<DOC>
	<DOCNO>NCT00631007</DOCNO>
	<brief_summary>This 24 week study compare efficacy four dose level INT131 besylate pioglitazone HCl patient type 2 diabetes . Eligible patient men woman ( non-childbearing potential use dual barrier method contraception ) 30 75 year age minimally responsive treatment sulfonylurea monotherapy sulfonylurea plus metformin combination therapy .</brief_summary>
	<brief_title>A Placebo Controlled Safety Efficacy Study INT131 Besylate Type 2 Diabetes , With Active Comparator</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosis Type 2 diabetes either sulfonylurea monotherapy sulfonylurea plus metformin combination therapy least 3 month stable dose Males Females ( nonchildbearing potential use dual barrier method contraception ) 30 75 year age HbA1c must ≥7.5 % ≤10 % screen Fasting Plasma Glucose must &lt; 240 mg/dL screen History type 1 diabetes History diabetic ketoacidosis NYHA Class III IV cardiac status hospitalization congestive heart failure within 6 week prior Visit 1 Treatment nonperoxisome proliferatoractivated receptor ( nonPPAR ) antidiabetic agent , investigational approve , metformin permit sulfonylurea within 3 month prior screen Treatment rosiglitazone , pioglitazone , PPAR investigational antidiabetic agent within 6 month prior screen Body mass index &gt; 45 kg/m2 Fasting triglycerides &gt; 500 mg/dL Uncontrolled hypertension ( sit systolic blood pressure &gt; 160 mmHg and/or sit diastolic blood pressure &gt; 100 mmHg Presence diabetic complication , opinion investigator , would complicate subject 's participation study ( i.e. , require initiation new medication )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>non-TZD</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>selective peroxisome proliferator-activated receptor gamma modulator</keyword>
	<keyword>SPPARM</keyword>
	<keyword>peroxisome proliferator-activated receptor gamma</keyword>
	<keyword>PPAR gamma</keyword>
	<keyword>insulin sensitizer</keyword>
	<keyword>glucose control</keyword>
	<keyword>endocrinopathy</keyword>
	<keyword>hypoglycemic agent</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>metformin</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>nutritional metabolic disease</keyword>
</DOC>